Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis
View More
Dialogues with the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: What Do Current Data for IO- and ALK-Targeted Strategies Tell Us?
March 19, 2024
Register Now!
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
View More
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care
View More
FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma can now receive lisocabtagene maraleucel after the FDA approved the drug, which was based on the phase 1/2 TRANSCEND CLL trial.
Nivolumab/Chemo Yields Meaningful Survival in Advanced Gastric/GEJ Cancer
Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.